Go Back to People
Gerald McMahon, Ph.D.
Chief Executive Officer, President and Director
Gerald McMahon, President and Chief Executive Officer, joined Kolltan in 2012. Dr. McMahon came to Kolltan from MedImmune, the biologics arm of AstraZeneca, where he served as Senior Vice President, R&D Oncology. In this position, he oversaw the strategy and investment for the oncologic biologics pipeline and was instrumental in licensing, partnering, and academic and corporate collaborations. Prior to joining MedImmune, Dr. McMahon was Venture Partner at Bay City Capital after previously heading two oncology development companies, Poniard Pharmaceuticals, where he was chairman and CEO, and NeoRx, where he served as CEO and President. Previously, Dr. McMahon held roles including that of President at SUGEN, which was acquired by Pfizer after SUGEN’s initial acquisition by Pharmacia & Upjohn. During his tenure at SUGEN, he held a critical role in the successful discovery, development, and regulatory approvals of novel oncology drugs, including Sutent® and Palladia®. Dr. McMahon was also Director at Sandoz, serving in various R&D roles prior to that company’s merger with Ciba-Geigy to form Novartis.
Dr. McMahon received his B.S. in Biology and Ph.D. in Biochemistry from Rensselaer Polytechnic Institute. He has held academic appointments at the Tufts University School of Medicine, Department of Hematology & Oncology at the New England Medical Center, and the Massachusetts Institute of Technology, and he has authored over 87 publications and holds 67 issued U.S. patents. Dr. McMahon currently serves on the Board of Directors of OXiGENE.